What Are Wall Street Analysts' Target Price for Biogen Stock?

Headquartered in Cambridge, Massachusetts, Biogen Inc. (BIIB) researches, develops, and commercializes therapies for severe neurological, immunological, and rare disorders. Commanding a market cap of approximately $28.8 billion, its portfolio spans treatments for multiple sclerosis, spinal muscular atrophy, Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), and other debilitating conditions. Over the past 52 weeks, Biogen’s shares have appreciated 41.9%, substantially outperforming the S&P 500 Ind ...